FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases
The session highlighted the progress of a next-gen gene therapy platform, with 4D-150 advancing in wet AMD and DME. Strong clinical data, rapid trial enrollment, and a robust commercial partnership with Otsuka support global expansion. Two-year data confirm safety and high treatment burden reductio…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.